

**Table 1: Demographics by Treatment (Safety Analysis Set)**

	(N = 40)
Age (years) <sup>a</sup>	
Mean (SD)	60.3
Median (Min, Max)	58.5 (32.0, 78.0)
Age group, n (%)	
<65 years	27 (67.5%)
≥65 years	13 (32.5%)
Sex, n (%)	
Male	14 (35.0%)
Female	26 (65.0%)
Race, n (%)	
Caucasian	29 (72.5%)
Indian	1 (2.5%)
Asian <sup>b</sup>	10 (25.0%)
Weight (kg)	
Mean (SD)	73.2 (15.4)
Median (Min, Max)	71.3 (48.5, 106.0)
Height (cm)	
Mean (SD)	166.1 (8.1)
Median (Min, Max)	167.5 (153.0, 185.0)
Body surface area (m <sup>2</sup> )	
Mean (SD)	1.8 (0.2)
Median (Min, Max)	1.8 (1.4, 2.2)
ECOG performance status, n (%)	
0	20 (50.0%)
1	20 (50.0%)

a Age at time of informed consent.

b Asian race was further broken down as follows: China (1 [2.6%] each for oPac+E and IV paclitaxel); Other, Taiwan (8 [20.5%] oPac+E and 7 [18.4%] IV paclitaxel); and Other, Philippines (1 [2.6%] each for oPac+E and IV paclitaxel).